576 related articles for article (PubMed ID: 24214315)
1. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
Pérez Ruixo JJ; Zheng J; Mandema JW
J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
[TBL] [Abstract][Full Text] [Related]
2. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
3. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
4. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
5. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
6. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
7. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
8. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
9. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
10. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
12. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
[TBL] [Abstract][Full Text] [Related]
14. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
15. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
16. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
17. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
Austin M; Yang YC; Vittinghoff E; Adami S; Boonen S; Bauer DC; Bianchi G; Bolognese MA; Christiansen C; Eastell R; Grauer A; Hawkins F; Kendler DL; Oliveri B; McClung MR; Reid IR; Siris ES; Zanchetta J; Zerbini CA; Libanati C; Cummings SR;
J Bone Miner Res; 2012 Mar; 27(3):687-93. PubMed ID: 22095631
[TBL] [Abstract][Full Text] [Related]
18. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
19. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
Bolognese MA; Teglbjærg CS; Zanchetta JR; Lippuner K; McClung MR; Brandi ML; Høiseth A; Lakatos P; Moffett AH; Lorenc RS; Wang A; Libanati C
J Clin Densitom; 2013; 16(2):147-53. PubMed ID: 22521543
[TBL] [Abstract][Full Text] [Related]
20. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
